.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
QuintilesIMS
McKesson
Federal Trade Commission
McKinsey
Chubb
Fish and Richardson
Queensland Health
Novartis

Generated: November 18, 2017

DrugPatentWatch Database Preview

Rempex Pharms Medcns Company Profile

« Back to Dashboard

What is the competitive landscape for REMPEX PHARMS MEDCNS, and what generic alternatives to REMPEX PHARMS MEDCNS drugs are available?

REMPEX PHARMS MEDCNS has one approved drug.

There are two US patents protecting REMPEX PHARMS MEDCNS drugs.

There are sixteen patent family members on REMPEX PHARMS MEDCNS drugs in fourteen countries.

Summary for Rempex Pharms Medcns

International Patents:16
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms Medcns
VABOMERE
meropenem; vaborbactam
POWDER;IV (INFUSION)209776-001Aug 29, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Rempex Pharms Medcns
VABOMERE
meropenem; vaborbactam
POWDER;IV (INFUSION)209776-001Aug 29, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Rempex Pharms Medcns

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,296,763Cyclic boronic acid ester derivatives and therapeutic uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Rempex Pharms Medcns Drugs

Country Document Number Estimated Expiration
Singapore187757► Subscribe
Russian Federation2599791► Subscribe
China103180328► Subscribe
Brazil112013003045► Subscribe
European Patent Office2603514► Subscribe
New Zealand607354► Subscribe
Japan2017052794► Subscribe
Canada2807546► Subscribe
Russian Federation2013104951► Subscribe
Chile2013000399► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Healthtrust
Express Scripts
Queensland Health
Mallinckrodt
Federal Trade Commission
Fish and Richardson
Covington
Chubb
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot